Welcome to chemicalbook!
010-86108875
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook >> CAS DataBase List >> C18 3'-sulfo Galactosylceramide-d3 (d18:1/18:0-d3)

C18 3'-sulfo Galactosylceramide-d3 (d18:1/18:0-d3)

C18 3'-sulfo Galactosylceramide-d3 (d18:1/18:0-d3) price.
2 prices
Selected condition:
Brand
  • Cayman Chemical
Package
  • 1mg
  • ManufacturerCayman Chemical
  • Product number24624
  • Product descriptionC18 3'-sulfo Galactosylceramide-d3 (d18:1/18:0-d3) ≥99% deuterated forms (d1-d3)
  • Packaging1mg
  • Price$669
  • Updated2024-03-01
  • Buy
  • ManufacturerCayman Chemical
  • Product number24624
  • Product descriptionC18 3''-sulfo Galactosylceramide-d3 (d18:1/18:0-d3) ≥99%deuteratedforms(d1-d3)
  • Packaging1mg
  • Price$736
  • Updated2026-04-30
  • Buy
Manufacturer Product number Product description Packaging Price Updated Buy
Cayman Chemical 24624 C18 3'-sulfo Galactosylceramide-d3 (d18:1/18:0-d3) ≥99% deuterated forms (d1-d3) 1mg $669 2024-03-01 Buy
Cayman Chemical 24624 C18 3''-sulfo Galactosylceramide-d3 (d18:1/18:0-d3) ≥99%deuteratedforms(d1-d3) 1mg $736 2026-04-30 Buy

Properties

solubility :Chloroform:
Methanol:
Water: (2:1:0.1): soluble

Safety Information

Symbol(GHS):
Signal word:
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
Precautionary statements:

Description

C18 3'-sulfo Galactosylceramide-d3 (d18:1/18:0-d3) is intended for use as an internal standard for the quantification of C18 3'-sulfo galactosylceramide (Item No. 24863) by GC- or LC-MS. C18 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It is a minor endogenous sphingolipid produced from C18 ceramide (Item No. 19556) and UDP-galactose in the endoplasmic reticulum followed by sulfation in the Golgi apparatus.1 C18 3'-sulfo Galactosylceramide levels are increased in brain tissue isolated from mice with an arylsulfatase A deficiency (ASA-KO), particularly in lipid raft fractions.2,3 Plasma levels of C18 3’-sulfo galactosylceramide positively correlate with disability progression in patients with relapsing-remitting multiple sclerosis using the Expanded Disability Status Scale.4 It is also increased in plasma from patients with metachromatic leukodystrophy (MLD).5 Brain levels of short-chain sulfatides, including C18 3’-sulfo galactosylceramide, decrease with age in mice and humans.2,6 As this product is derived from a natural source, there may be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1536]WARNING This product is not for human or veterinary use.